Raptor Pharmaceutical Announces Pricing of Public Offering

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Raptor Pharmaceutical Announces Pricing of Public Offering of Common Stock

NOVATO, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP ), a biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases, today announced that it has priced an underwritten public offering of 9,500,000 shares of its common stock at a price to the public of $9.00 per share. In addition, Raptor has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,425,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Gross proceeds before underwriting discounts and commissions and estimated expenses of the offering payable by the company are expected to be approximately $85.5 million, or approximately $98.3 million if the underwriters exercise their option to purchase the additional shares in full. The offering is expected to close on April 8, 2015, subject to customary closing conditions. All of the shares are being offered by the company.

Citigroup, Leerink Partners and Cowen and Company are acting as lead joint book-running managers for the offering. JMP Securities is acting as lead manager and Janney Montgomery Scott is acting as a co-manager for the offering.

A registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) and became automatically effective on March 30, 2015. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov . When available, copies of the final prospectus supplement and accompanying prospectus related to the offering may also be obtained from Citigroup Global Markets Inc., Attention: c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, New York, 11717, or by phone at (800) 831-9146, or by email at prospectus@citi.com ; or from the offices of Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02110, or by phone at (800) 808-7525, or by email at syndicate@leerink.com .

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.

About Raptor Pharmaceutical

Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic steatohepatitis (NASH), and Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including exclusivity for nephropathic cystinosis in the U.S. and EU, and orphan drug designation for HD in the U.S. and EU.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the anticipated public offering, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our actual results to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the completion of the public offering on the anticipated terms and the satisfaction of customary closing conditions related to the public offering, among others. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see Raptor's Registration Statement on Form S-3 filed with the SEC on March 30, 2015, as may be amended from time to time, together with its preliminary prospectus supplement relating to the proposed offering filed with the SEC, and the documents incorporated by reference therein, including its Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 2, 2015, and its subsequent periodic reports filed with the SEC, including under the caption "Risk Factors". Raptor undertakes no obligation to update or revise any forward-looking statements.

COMPANY CONTACT: Kimberly Lee, D.O. Vice President, Corporate Strategy and Communications Raptor Pharmaceutical Corp. (415) 408-6351 INVESTOR CONTACT: Westwicke Partners, LLC Robert H. Uhl Managing Director (858) 356-5932 MEDIA CONTACT: Cammy Duong Canale Communications (619) 849-5382

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 90

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 102

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 88

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 101

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 112

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 257

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading

Top 5 Most Recently Viewed Articles

La-Z-Boy Faces Major Stock Decline After Weak Earnings Report

Updated Category News Views 264

La-Z-Boy Stock Experiences Significant Drop La-Z-Boy Incorporated (NYSE: LZB) witnessed a dramatic 23.55% decline in after-hours trading, with shares plummeting from $39.11 to $29.90. This downturn followed the release of disappointing first-quarter results that did not meet analysts' expectations, prompting concerns about operational challenges. Disappointing Earnings...

Continue Reading
CLEAR Secure, Inc. Reveals Impressive Q3 2025 Performance

Updated Category News Views 224

CLEAR Secure, Inc.'s Q3 2025 Financial Overview CLEAR Secure, Inc. (NYSE: YOU), the leader in secure identity technologies, has recently unveiled its financial highlights for the third quarter of the 2025 fiscal year. As an innovative firm at the forefront of identity verification, CLEAR continues to address the growing needs in the security sector amid increasing cyber...

Continue Reading
Ameren Corporation Celebrates 10 Years of Disability Inclusion

Updated Category News Views 62

Ameren Corporation Champions Disability Inclusion Ameren Corporation (NYSE: AEE) has made impressive advancements in promoting disability inclusion, scoring a perfect 100 on the Disability Equality Index for the tenth year running. This recognition highlights Ameren’s role as a leader in fostering an inclusive workplace that values diversity and actively supports...

Continue Reading
Labcorp Faces Lawsuit: Wiretapping Accusations Surface

Updated Category News Views 60

Labcorp's Legal Tangle Unveiled One minute you're on Labcorp's website searching for medical info, the next you're caught up in a class-action legal whirlwind. Legal drama is not on any patient’s checklist, but here we are, with Labcorp knee-deep in some serious allegations. The crux of the matter points to alleged wiretapping violations, with claims that Labcorp,...

Continue Reading
Advent's $2.5 Billion Acquisition of Sapiens: A New Era Looms

Updated Category News Views 203

Advent to Acquire Sapiens for $2.5 Billion Sapiens International Corporation N.V. (NASDAQ: SPNS), a leader in software solutions for the insurance sector, has seen its stock price soar following the exciting announcement that it will be acquired by global private equity firm Advent. The all-cash acquisition deal is valued at approximately $2.5 billion, indicating a...

Continue Reading